Thein D, Roseno NAL, Maul JT, Wu JJ, et al. Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 years of treatment - a nationwide cohort study. J Invest Dermatol 2023 Apr 27:S0022-202X(23)02041.
PMID: 37119965